Pathkey.Ai (PKY) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
3 Aug

Can PathKey.AI (ASX:PKY) Turn Two AI Engines Into Commercial Growth?

Highlights PathKey.AI is developing separate artificial intelligence platforms for semiconductor design and clinical trial planning. Chipforge aims to reduce errors and delays across complex chip-development workflows. TrialKey uses clinical-trial data to identify protocol weaknesses before patient recruitment begins. PathKey.AI (ASX:PKY) is attracting attention with an unusual dual-platform strategy spanning semiconductor engineering and biotechnology. Its Chipforge platform is designed to au...

Kalkine
Neutral
10 July

LTDPATHKEY.AI Plans to Issue 2 Million Shares and 30 Million Options for Corporate Advisory Services

LTDPATHKEY.AI (ASX: PKY) has revealed plans to issue 2,000,000 ordinary shares along with 30,000,000 options as part of a corporate advisory agreement. This issuance depends on successfully recruiting an appropriate adviser, director, or manager. This move highlights the company's strategic initiative to strengthen its advisory team and enhance investor confidence. Key Points Company: LTDPATHKEY.AI, ASX ticker: PKY Planned issuance of 2,000,000 ordinary shares and 30,000,000 options Scheduled...